Picture of Stereotaxis logo

STXS — Stereotaxis News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Stereotaxis Q2 revenue misses estimates, dragged by system decline

Stereotaxis Q2 revenue misses estimates, dragged by system decline


Overview

  • Surgical robotics firm's Q2 revenue declined yr/yr and missed analyst expectations

  • System revenue fell due to lack of robotic system deliveries, partly offset by Synchrony sales

  • Company completed previously announced Robocath acquisition, expanding endovascular technology portfolio


Outlook

  • Company expects recurring revenue to reach $7 mln in Q3 and $8 mln in Q4 2026

  • Stereotaxis projects system revenue of about $3 mln in both Q3 and Q4 2026

  • Company anticipates reaching cash flow profitability in the first half of 2027


Result Drivers

  • SYSTEM REVENUE DECLINE - Co said lack of robotic system deliveries led to lower system revenue, partly offset by initial Synchrony sales

  • RECURRING REVENUE GROWTH - Recurring revenue increased due to contributions from new robotic catheters, despite procedural pressure from limited catheter supply

  • ROBOCATH ACQUISITION - Co completed Robocath acquisition, aiming to strengthen robotic technology leadership across endovascular procedures


Company press release: ID:nGNX1lYNCD


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$7.67 mln

$8.35 mln (4 Analysts)

Q2 Net Loss

$4.47 mln

Q2 Operating Expenses

$9.05 mln

Q2 Operating Income

-$4.57 mln

Q2 Disposable, service and accesories revenue

$6.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Stereotaxis Inc is $4.00, about 177.8% above its August 10 closing price of $1.44


Reuters Recommended Reads

  • Aug 10 - Orchestra BioMed Q2 revenue drops, net loss widens

  • Aug 10 - Ceribell Q2 revenue beats estimates; raises 2026 revenue outlook

  • Aug 10 - Surgery Partners Q2 revenue beats on growth in same-facility segment


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Stereotaxis

See all news